Home > Cardiology > AHA 2021 > COVID-19 & the Heart > Neutral effect of P2Y12 inhibitors in non-critical COVID-19 hospitalisations

Neutral effect of P2Y12 inhibitors in non-critical COVID-19 hospitalisations

Presented By
Prof. Jeffrey Berger, New York University Langone, USA
Conference
AHA 2021
Trial
ACTIV-4A
Treatment with P2Y12 inhibitors for non-critically ill hospitalised patients with COVID-19 was not associated with a reduced number of organ support-free days or deaths in the phase 4 ACTIV-4A trial. The incidence of major bleeding events was low. P2Y12 inhibitors are currently being evaluated in critically ill hospitalised patients with COVID-19 [1]. Prof. Jeffrey Berger (New York University Langone, NY, USA) highlighted that approximately 1 out of 4 non-critically ill hospitalised patients with COVID-19 treated with therapeutic-dose heparin dies or needs intensive care level support, demonstrating a clear need for additional therapies in this population. In addition, there is evidence that platelets are associated with thrombotic events, organ failure, and death in patients with COVID-19 [2–4]. Thus, the randomised, open-label ACTIV-4A trial (NCT04505774) investigated the...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on